Bullseye Asset Management LLC Sells 2,701 Shares of Cryoport, Inc. (NASDAQ:CYRX)

Bullseye Asset Management LLC lessened its holdings in shares of Cryoport, Inc. (NASDAQ:CYRX) by 1.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 211,563 shares of the company’s stock after selling 2,701 shares during the period. Bullseye Asset Management LLC’s holdings in Cryoport were worth $1,646,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of the business. Franklin Resources Inc. boosted its holdings in Cryoport by 0.4% during the 4th quarter. Franklin Resources Inc. now owns 387,131 shares of the company’s stock valued at $3,012,000 after acquiring an additional 1,512 shares during the period. Rhumbline Advisers lifted its position in shares of Cryoport by 2.9% during the fourth quarter. Rhumbline Advisers now owns 63,284 shares of the company’s stock worth $492,000 after purchasing an additional 1,764 shares during the last quarter. Nebula Research & Development LLC boosted its stake in shares of Cryoport by 21.6% during the fourth quarter. Nebula Research & Development LLC now owns 12,442 shares of the company’s stock valued at $97,000 after purchasing an additional 2,207 shares during the period. Penbrook Management LLC grew its holdings in shares of Cryoport by 6.0% in the fourth quarter. Penbrook Management LLC now owns 52,570 shares of the company’s stock worth $409,000 after purchasing an additional 2,975 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD grew its holdings in shares of Cryoport by 8.9% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 60,003 shares of the company’s stock worth $467,000 after purchasing an additional 4,902 shares during the last quarter. Institutional investors own 92.90% of the company’s stock.

Insiders Place Their Bets

In other Cryoport news, CEO Jerrell Shelton sold 4,620 shares of the company’s stock in a transaction on Monday, March 17th. The stock was sold at an average price of $6.29, for a total value of $29,059.80. Following the completion of the sale, the chief executive officer now directly owns 765,399 shares in the company, valued at $4,814,359.71. This represents a 0.60 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders have sold a total of 19,830 shares of company stock valued at $118,353 in the last 90 days. 10.10% of the stock is owned by insiders.

Cryoport Stock Up 5.4 %

Cryoport stock opened at $5.89 on Friday. The business’s 50-day moving average price is $5.90 and its 200 day moving average price is $6.95. The company has a quick ratio of 5.32, a current ratio of 5.70 and a debt-to-equity ratio of 0.48. The firm has a market cap of $293.97 million, a price-to-earnings ratio of -1.74 and a beta of 1.81. Cryoport, Inc. has a 52 week low of $4.58 and a 52 week high of $17.41.

Cryoport (NASDAQ:CYRX) last issued its quarterly earnings data on Tuesday, March 4th. The company reported ($0.42) EPS for the quarter, missing the consensus estimate of ($0.33) by ($0.09). The business had revenue of $59.53 million during the quarter, compared to analyst estimates of $58.71 million. Cryoport had a negative net margin of 70.08% and a negative return on equity of 13.35%. During the same period in the previous year, the business posted ($0.29) earnings per share. As a group, sell-side analysts anticipate that Cryoport, Inc. will post -0.99 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have commented on the stock. Needham & Company LLC restated a “buy” rating and issued a $11.00 target price on shares of Cryoport in a research note on Wednesday, April 16th. UBS Group boosted their price target on Cryoport from $10.00 to $11.00 and gave the company a “buy” rating in a report on Tuesday, April 1st. Roth Mkm restated a “buy” rating and set a $15.00 price objective on shares of Cryoport in a report on Tuesday, April 1st. Finally, Guggenheim reiterated a “buy” rating and issued a $10.00 target price on shares of Cryoport in a report on Wednesday, April 16th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $11.67.

About Cryoport

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.